A5012342866- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- Ferroptosis and cancer prognosis
- Blood Coagulation and Thrombosis Mechanisms
- Immune Cell Function and Interaction
- Cannabis and Cannabinoid Research
- Platelet Disorders and Treatments
- Protein Degradation and Inhibitors
- Advanced Biosensing Techniques and Applications
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses
- Reproductive System and Pregnancy
- Renal function and acid-base balance
- Colorectal Cancer Surgical Treatments
- Mathematical Biology Tumor Growth
- Central Venous Catheters and Hemodialysis
- Blood groups and transfusion
- Sleep and Wakefulness Research
- Colorectal and Anal Carcinomas
- Ion Channels and Receptors
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
Hammersmith Hospital
2018
Imperial College London
2009-2018
Chelsea and Westminster Hospital
2009-2016
The London College
2016
Hillingdon Hospital
2012
Abstract Purpose: We aimed to establish whether programmed cell death-1 (PD-1) and death ligand 1 (PD-L1) expression, in ovarian cancer tumor tissue blood, could be used as biomarkers for discrimination of histology prognosis cancer. Experimental Design: Immune cells were separated from ascites, obtained women with suspected studied the differential expression possible immune using flow cytometry. PD-L1 on tumor-associated inflammatory was assessed by immunohistochemistry microarray. Plasma...
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological malignancies in UK. Recent evidence has shown that there potential for immunotherapies to be successful treating this cancer. We have previously effective application combinations traditional chemotherapy and CAR (chimeric antigen receptor) T cell immunotherapy vitro vivo models EOC. Platinum-based synergizes with ErbB-targeted cells (named T4), significantly reducing tumor burden mice. Here, we show paclitaxel T4 as...
Elevation of intracellular Ca2+ concentration induces the synthesis N-arachydonoylethanolamine (anandamide) in a subpopulation primary sensory neurons. N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) is only known enzyme that synthesizes anandamide -dependent manner. NAPE-PLD mRNA as well anandamide's main targets, excitatory transient receptor potential vanilloid type 1 ion channel (TRPV1), inhibitory cannabinoid (CB1) receptor, and anandamide-hydrolyzing fatty acid amide...
Our previous finding, that the capsaicin- and KCl-induced Ca(2+)-dependent production of intra- intercellular signaling molecule N-arachidonoyl ethanolamine (anandamide) in cultured primary sensory neurons could be abolished reduced by approximately 2/3 capsaicin-induced degeneration capsaicin-sensitive neurons, respectively suggests a major sub-population cells together with group non-capsaicin-sensitive should express enzymes involved anandamide synthesis. N-acyl phosphotidylethanolamine...
<p>REMARK flow diagram to show the patient groups used in each part of study. Groups have been ringed colour denote which study these data were used. Of 71 EOC patients who donated blood and/or ascites, eight only ascites.</p>
<p>Differential expression of immune markers on PBMCs in patients with benign tumours and high grade serous (HGS) the discovery validation cohorts. A: The percentage monocytes lymphocytes (and their subsets) from or HGS that expressed PD-1, PD-L1 CD69 set. B: Differential PBMC between set.</p>
<p>The stability of unsupervised hierarchical clustering candidate biomarkers A: 23 markers in PBMC samples, B: 22 ascites samples. Healthy controls (HH), benign ovarian tumours (BN), borderline tumour (BT) and malignant cases (SER: serous; END: endometrioid; CC: clear cell; MU: mucinous). The was estimated by pvclust package R (see method).</p>
<p>Differential expression of immune markers AMCs in patients with benign tumours and EOCs the discovery set. The percentage monocytes lymphocytes (and their subsets) ascites that expressed PD-1, PD-L1 CD69 was determined. Analysis PD-L1+ CD11c+ cells omitted due to missing data points. Statistical analysis performed using Mann-Whitney U test.</p>
<p>Receiver operating characteristic curves comparing individual markers and combined against CA-125. A: Sensitivity specificity of discriminating EOCs from benign tumours when using PD-L1+ monocytes (AUC 0.93), PD-L1+CD14+ with PD-1+ lymphocytes 0.92) compared to B: HGS 0.98), 0.97) CA-125.</p>
<p>Flow cytometry gating for blood and ascites mononuclear cells. Forward sideward scatter plots were used to set initial gates identify lymphocytes granulocyte populations in (A) (B). Dead cell population was identified using PI staining. Subsequent isotype controls all the fluorochromes so that bottom left quadrant had at least 99% of gated population. An example lymphocyte stained FITC PE is shown (C).</p>
<div>Abstract<p><b>Purpose:</b> We aimed to establish whether programmed cell death-1 (PD-1) and death ligand 1 (PD-L1) expression, in ovarian cancer tumor tissue blood, could be used as biomarkers for discrimination of histology prognosis cancer.</p><p><b>Experimental Design:</b> Immune cells were separated from ascites, obtained women with suspected studied the differential expression possible immune using flow cytometry. PD-L1 on...
<div>Abstract<p><b>Purpose:</b> We aimed to establish whether programmed cell death-1 (PD-1) and death ligand 1 (PD-L1) expression, in ovarian cancer tumor tissue blood, could be used as biomarkers for discrimination of histology prognosis cancer.</p><p><b>Experimental Design:</b> Immune cells were separated from ascites, obtained women with suspected studied the differential expression possible immune using flow cytometry. PD-L1 on...
<p>REMARK flow diagram to show the patient groups used in each part of study. Groups have been ringed colour denote which study these data were used. Of 71 EOC patients who donated blood and/or ascites, eight only ascites.</p>
<p>The stability of unsupervised hierarchical clustering candidate biomarkers A: 23 markers in PBMC samples, B: 22 ascites samples. Healthy controls (HH), benign ovarian tumours (BN), borderline tumour (BT) and malignant cases (SER: serous; END: endometrioid; CC: clear cell; MU: mucinous). The was estimated by pvclust package R (see method).</p>
<p>Flow cytometry gating for blood and ascites mononuclear cells. Forward sideward scatter plots were used to set initial gates identify lymphocytes granulocyte populations in (A) (B). Dead cell population was identified using PI staining. Subsequent isotype controls all the fluorochromes so that bottom left quadrant had at least 99% of gated population. An example lymphocyte stained FITC PE is shown (C).</p>
<p>Differential expression of immune markers AMCs in patients with benign tumours and EOCs the discovery set. The percentage monocytes lymphocytes (and their subsets) ascites that expressed PD-1, PD-L1 CD69 was determined. Analysis PD-L1+ CD11c+ cells omitted due to missing data points. Statistical analysis performed using Mann-Whitney U test.</p>
<p>Differential expression of immune markers on PBMCs in patients with benign tumours and high grade serous (HGS) the discovery validation cohorts. A: The percentage monocytes lymphocytes (and their subsets) from or HGS that expressed PD-1, PD-L1 CD69 set. B: Differential PBMC between set.</p>